MQS Management’s Vanda Pharmaceuticals VNDA Stock Holding History

MQS Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,488	Closed	-$104K	–	597
2022 Q3	$104K	Buy	+10,488	New	+$111K	0.07%	375

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MQS Management's VNDA Position: Q4 2022 in Review

MQS Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2022, closing a stake of 10,488 shares — an estimated $104K sold.

MQS Management first reported a position in VNDA in Q3 2022 and held it in 1 quarter. The position peaked at $104K in Q3 2022. 190 funds tracked by Wall St. Rank hold VNDA as of Q4 2022.

MQS Management reported no remaining Vanda Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
MQS Management sold 10,488 Vanda Pharmaceuticals shares in Q4 2022, an estimated $104K.
MQS Management first reported a position in Vanda Pharmaceuticals in Q3 2022 and held it in 1 quarter.
MQS Management's Vanda Pharmaceuticals position peaked at $104K in Q3 2022.
190 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2022.

Based on MQS Management's 13F filing for Q4 2022, filed 10 Feb 2023.